<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05119686</url>
  </required_header>
  <id_info>
    <org_study_id>AR882-202</org_study_id>
    <nct_id>NCT05119686</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of AR882 in Gout Patients</brief_title>
  <official_title>A Phase 2b, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of AR882 Versus Placebo in Gout Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arthrosi Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arthrosi Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the serum uric acid lowering effect and safety of AR882 in gout&#xD;
      patients at two doses compared to placebo over 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum urate (uric acid) (sUA) level &lt; 6 mg/dL following 6 weeks of dosing</measure>
    <time_frame>6 weeks</time_frame>
    <description>Comparison of the treatment groups for the proportion of patients with serum urate (uric acid) (sUA) level &lt; 6 mg/dL following 6 weeks of dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sUA levels &lt; 5, &lt; 4, and &lt; 3 mg/dL</measure>
    <time_frame>6 weeks</time_frame>
    <description>Comparison of the treatment groups for proportion of patients whose sUA levels are &lt; 5, &lt; 4, and &lt; 3 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>14 weeks</time_frame>
    <description>Adverse event and serious adverse event incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Plasma samples will be collected to assess plasma concentrations at a series of timepoints to derive Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to observed Cmax (Tmax)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Plasma samples will be collected to assess plasma concentrations at a series of timepoints to derive Tmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Plasma samples will be collected to assess plasma concentrations at a series of timepoints to derive AUC.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Gout</condition>
  <condition>Arthritis, Gouty</condition>
  <condition>Hyperuricemia</condition>
  <condition>Gout Chronic</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AR882 Dose 1 x 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AR882 Dose 1 x 2 weeks, then Dose 2 x 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>AR882 matching placebo x 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AR882 Dose 1</intervention_name>
    <description>Solid Oral Capsule</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AR882 Dose 2</intervention_name>
    <description>Solid Oral Capsule</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Solid Oral Capsule Placebo</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of gout&#xD;
&#xD;
          -  sUA &gt; 7 mg/dL&#xD;
&#xD;
          -  Estimated Glomerular Filtration Rate (eGFR) â‰¥ 30 mL/min/1.73m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Malignancy within 5 years, except for successfully treated basal or squamous cell&#xD;
             carcinoma of the skin&#xD;
&#xD;
          -  History of cardiac abnormalities&#xD;
&#xD;
          -  History of kidney stones&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R Keenan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Arthrosi Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Director Clinical Operations</last_name>
    <phone>+1 949-393-2676</phone>
    <email>info@arthrosi.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
    <mesh_term>Arthritis, Gouty</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

